Results 11 to 20 of about 1,115 (163)

Thrombotic Complications in Immune Thrombocytopenia Patients Treated With Avatrombopag

Hematology Reports, 2023
Avatrombopag is a novel oral non-peptide thrombopoietin receptor agonist (TPO-RA) that was approved by the FDA as a second-line therapy for chronic immune thrombocytopenia (cITP).
Spero R Cataland, Steven Dean
exaly   +4 more sources

Efficacy and Safety Evaluation of Avatrombopag in Immune Thrombocytopenia: Analyses of a Phase III Study and Long-Term Extension

Platelets, 2022
Avatrombopag is an oral thrombopoietin receptor agonist approved for chronic immune thrombocytopenia (ITP). This is a post hoc analysis of the pivotal phase III study (NCT01438840) evaluating additional endpoints not previously described.
Hanny Al-Samkari, Srikanth Nagalla
exaly   +3 more sources

Avatrombopag in heavily pretreated chronic immune thrombocytopenia: a single center experience from Oman [PDF]

Frontiers in Medicine
BackgroundChronic immune thrombocytopenia (ITP) is characterized by persistent thrombocytopenia and bleeding risk, and a subset of patients remains refractory or relapses despite multiple lines of therapy.
Nashwa Al-Sharji, Bushra Salman, Shireen Al-Zadjali, Mohammed Al-Huneini   +3 more
doaj   +3 more sources

Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis [PDF]

Frontiers in Public Health
ObjectivesThrombopoietin receptor agonists (TPO-RAs) are standard second-line therapies for chronic immune thrombocytopenia (ITP). Given the introduction of domestic options like hetrombopag, a comparative economic evaluation is essential to inform ...
Shanshan Jin, Shanshan Jin, Shanshan Jin, Zhengqiang Hu, Yuancheng Jin, Wang Lv, Zhujin Song, Su Zeng, Su Zeng, Miaolian Wu, Miaolian Wu, Miaolian Wu   +11 more
doaj   +3 more sources

Avatrombopag Ethnic Sensitivity Analysis in Chronic Liver Disease and Thrombocytopenia Patients: Individual-Level Pooled Analysis

Therapeutic Advances in Gastroenterology, 2022
Introduction: Few data have been published on the ethnic sensitivity of effectiveness, pharmacokinetics (PK), and pharmacodynamics (PD) of avatrombopag for the management of thrombocytopenia in patients with chronic liver disease (CLD).
Ai-Min Hui
exaly   +3 more sources

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial. [PDF]

Br J Haematol
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Grace RF, Leblebisatan G, Aydinok Y, Unal S, Grainger J, Grimes AB, Lambert MP, Zhang J, Jamieson BD, Sattar F, Kolodny S, Vredenburg M, AVA‐PED‐301 Study Group.   +12 more
europepmc   +3 more sources

Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia

Platelets, 2023
Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA) that was approved in the US in 2019 for treatment of chronic immune thrombocytopenia (ITP).
Shivi Jain, Terry Gernsheimer, Scott Kolodny, Chelsea Bernheisel, Michael Vredenburg, Sandhya R. Panch   +5 more
doaj   +2 more sources

Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments [PDF]

Journal of Market Access & Health Policy, 2023
Introduction: Primary immune thrombocytopenia is a rare autoimmune disease characterised by a decreased platelet count resulting in an increased risk of bleeding events and even life-threatening haemorrhages.
Andrea Aiello, Elisa Elena Mariano, Mariangela Prada, Cristina Teruzzi, Nicoletta Martone, Stefano Capri, Giuseppe Carli, Sergio Siragusa   +7 more
doaj   +2 more sources

Avatrombopag for the salvage treatment of platelet transfusion refractoriness

Therapeutic Advances in Hematology
Background: Platelet transfusion refractoriness (PTR) is a life-threatening and intractable condition in hematological patients. Thrombopoietin receptor agonists such as avatrombopag promote platelet production and modulate immune intolerance.
Yuehong Qin, Yu Wang, Yujiao Zhang, Yingying Jiao, Jieyu Ye   +4 more
doaj   +4 more sources

Avatrombopag: A Review in Thrombocytopenia [PDF]

Drugs, 2021
Avatrombopag (Doptelet®) is an orally administered second generation thrombopoietin receptor agonist (TPO-RA) approved for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory or have an unsatisfactory response to other treatments, as well as for the treatment of thrombocytopenia in adult patients with ...
Anthony Markham (4891627)
openaire   +3 more sources